

[COMMITTEE PRINT]

(SHOWING H.R. 4641, AS FORWARDED BY THE SUBCOMMITTEE ON HEALTH
ON APRIL 20, 2016)

114TH CONGRESS
2D SESSION

H. R. 4641

To provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

FEBRUARY 26, 2016

Mrs. BROOKS of Indiana (for herself and Mr. KENNEDY) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. DEVELOPMENT OF BEST PRACTICES FOR THE**
4 **USE OF PRESCRIPTION OPIOIDS.**

5 (a) DEFINITIONS.—In this section—

1 (1) the term “Secretary” means the Secretary
2 of Health and Human Services; and

3 (2) the term “task force” means the Pain Man-
4 agement Best Practices Inter-Agency Task Force
5 convened under subsection (b).

6 (b) INTER-AGENCY TASK FORCE.—Not later than
7 December 14, 2018, the Secretary, in cooperation with the
8 Secretary of Veterans Affairs, the Secretary of Defense,
9 and the Administrator of the Drug Enforcement Adminis-
10 tration, shall convene a Pain Management Best Practices
11 Inter-Agency Task Force to review, modify, and update,
12 as appropriate, best practices for pain management (in-
13 cluding chronic and acute pain) and prescribing pain
14 medication.

15 (c) MEMBERSHIP.—The task force shall be comprised
16 of—

17 (1) representatives of—

18 (A) the Department of Health and Human
19 Services;

20 (B) the Department of Veterans Affairs;

21 (C) the Food and Drug Administration;

22 (D) the Department of Defense;

23 (E) the Drug Enforcement Administration;

24 (F) the Centers for Disease Control and
25 Prevention;

- 1 (G) the Indian Health Service;
- 2 (H) the National Academy of Medicine;
- 3 (I) the National Institutes of Health;
- 4 (J) the Office of National Drug Control
- 5 Policy; and
- 6 (K) the Substance Abuse and Mental
- 7 Health Services Administration;
- 8 (2) physicians, dentists, and nonphysician pre-
- 9 scribers;
- 10 (3) pharmacists;
- 11 (4) experts in the fields of pain research and
- 12 addiction research;
- 13 (5) representatives of—
- 14 (A) pain management professional organi-
- 15 zations;
- 16 (B) the mental health treatment commu-
- 17 nity;
- 18 (C) the addiction treatment and recovery
- 19 community;
- 20 (D) pain advocacy groups; and
- 21 (E) groups with expertise around overdose
- 22 reversal;
- 23 (6) a person in recovery from addiction to medi-
- 24 cation for chronic pain;
- 25 (7) a person with chronic pain; and

1 (8) other stakeholders, as the Secretary deter-
2 mines appropriate.

3 (d) DUTIES.—The task force shall—

4 (1) not later than 180 days after the date on
5 which the task force is convened under subsection
6 (b), review, modify, and update, as appropriate, best
7 practices for pain management (including chronic
8 and acute pain) and prescribing pain medication,
9 taking into consideration—

10 (A) existing pain management research;

11 (B) recommendations from relevant con-
12 ferences and existing relevant evidence-based
13 guidelines;

14 (C) ongoing efforts at the State and local
15 levels and by medical professional organizations
16 to develop improved pain management strate-
17 gies, including consideration of the availability
18 of opioids with abuse deterrent technology as
19 well as pharmacological and medical device al-
20 ternatives to opioids to reduce opioid
21 monotherapy in appropriate cases;

22 (D) the management of high-risk popu-
23 lations, other than populations who suffer pain,
24 who—

1 (i) may use or be prescribed
2 benzodiazepines, alcohol, and diverted
3 opioids; or

4 (ii) receive opioids in the course of
5 medical care; and

6 (E) the 2016 Guideline for Prescribing
7 Opioids for Chronic Pain issued by the Centers
8 for Disease Control and Prevention;

9 (2) solicit and take into consideration public
10 comment on the practices developed under para-
11 graph (1), amending such best practices if appro-
12 priate; and

13 (3) develop a strategy for disseminating infor-
14 mation about the best practices developed under
15 paragraphs (1) and (2) to prescribers, pharmacists,
16 State medical boards, educational institutions that
17 educate prescribers and pharmacists, and other par-
18 ties, as the Secretary determines appropriate.

19 (e) LIMITATION.—The task force shall not have rule-
20 making authority.

21 (f) REPORT.—Not later than 270 days after the date
22 on which the task force is convened under subsection (b),
23 the task force shall submit to Congress a report that in-
24 cludes—

1 (1) the strategy for disseminating best practices
2 for pain management (including chronic and acute
3 pain) and prescribing pain medication, as developed
4 under subsection (d);

5 (2) the results of a feasibility study on linking
6 the best practices described in paragraph (1) to re-
7 ceiving and renewing registrations under section
8 303(f) of the Controlled Substances Act (21 U.S.C.
9 823(f)); and

10 (3) recommendations for effectively applying
11 the best practices described in paragraph (1) to im-
12 prove prescribing practices at medical facilities, in-
13 cluding medical facilities of the Veterans Health Ad-
14 ministration and Indian Health Service.